Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458133 | 1.00 | TACR1 (0.58) | TACR1NR1I2 | |
| SCHEMBL13935155 | 0.88 | TACR1 (0.75) | TACR1NR1I2 | |
| SCHEMBL13935103 | 0.87 | TACR1 (0.76) | TACR1NR1I2 | |
| SCHEMBL4472853 | 0.81 | TACR1 (0.75) | TACR1NR1I2 | |
| SCHEMBL4472850 | 0.81 | TACR1 (0.75) | TACR1NR1I2 | |
| SCHEMBL4459883 | 0.81 | TACR1 (0.53) | TACR1NR1I2 | |
| SCHEMBL4459879 | 0.81 | TACR1 (0.53) | TACR1NR1I2 | |
| SCHEMBL4460548 | 0.80 | TACR1 (0.75) | TACR1NR1I2 | |
| SCHEMBL13935156 | 0.78 | TACR1 (0.62) | TACR1NR1I2 | |
| SCHEMBL13935178 | 0.78 | TACR1 (0.77) | TACR1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | TACR1, PROKR1, TACR2 | TACR1 1/4885NR1I2 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.